SGHTHealthcare · Medical DevicesThe 7 Wall Street analysts covering Sight Sciences, Inc. hold a median 12-month price target of $8 — -1.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 12 Sept 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Sight Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (97): Analysts have, on balance, been raising their forecasts.
Volatility (13): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SGHT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −1.7% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Aug 2026 | UBS | Maintains | Buy | $7.00 → $8.00 |
| 28 July 2026 | UBS | Assumes | Buy | $11 → $7.00 |
| 8 July 2026 | Citigroup | Maintains | Neutral | $5.15 → $6.00 |
| 8 July 2026 | Citigroup | Maintains | Neutral | — |
| 28 May 2026 | Citigroup | Maintains | Neutral | — |
| 6 Mar 2026 | Citigroup | Maintains | Neutral | — |
| 6 Mar 2026 | UBS | Maintains | Buy | — |
| 2 Mar 2026 | Stifel | Maintains | Buy | — |
| 5 Jan 2026 | Piper Sandler | Upgrade | Overweight | — |
| 23 Dec 2025 | UBS | Maintains | Buy | — |
| 11 Dec 2025 | Citigroup | Maintains | Neutral | — |
| 10 Dec 2025 | Lake Street | Maintains | Buy | — |
| 2 Dec 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 10 Nov 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 7 Nov 2025 | Piper Sandler | Maintains | Neutral | — |
| 21 Oct 2025 | Lake Street | Maintains | Buy | — |
| 7 Oct 2025 | Citigroup | Maintains | Neutral | — |
| 28 Aug 2025 | Needham | Reiterates | Hold | — |
| 21 Aug 2025 | Citigroup | Maintains | Neutral | — |
| 8 Aug 2025 | Lake Street | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SGHT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Sight Sciences, Inc. returned +124.9% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 93% of US stocks
Cheaper than 23% of US stocks
Cheaper than 11% of US stocks
Cheaper than 90% of US stocks
Higher than 69% of US stocks
Higher than 58% of US stocks
Higher than 97% of US stocks
Higher than 22% of US stocks
Higher than 12% of US stocks
Higher than 22% of US stocks
Higher than 26% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Sight Sciences, Inc. has a market value of $448.4M and an enterprise value of $410.6M.
Revenue in the twelve months to 30 June 2026: $83.4M. The latest quarter grew 19.5% year on year.
Net income over the same four quarters: −$29.8M, a −35.7% net margin.
Diluted earnings per share, trailing twelve months: $−0.56.
Free cash flow in the twelve months to 30 June 2026: −$23.3M.
Trailing P/E: −11.0×; forward P/E: −18.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Sight Sciences, Inc. employs 186 people — $448K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Sight Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Sight Sciences, Inc. announced it will present at the upcoming Morgan Stanley Global Healthcare Conference in New York, NY. The presentation is scheduled for September 15.
Why it matters — The conference presentation gives Sight Sciences an opportunity to communicate its eyecare technology business to the healthcare investment community.
Sight Sciences announced that, effective August 18, 2026, the FDA updated the Indications for Use for its TearCare System, making it the first and only meibomian gland dysfunction (MGD) treatment indicated to improve meibomian gland function in patients with evaporative dry eye disease.
Why it matters — This regulatory update gives Sight Sciences' TearCare a differentiated, first-of-its-kind labeling claim that may strengthen its market position in the MGD treatment space.
Sight Sciences, Inc. published its Q2 2026 earnings call transcript via Seeking Alpha, covering the company's second-quarter results and management's remarks on its business performance during the call.
Why it matters — A SGHT watcher would care because the transcript offers management's own commentary on the company's Q2 2026 performance and outlook in its own words.
Sight Sciences (SGHT) reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjusted operating expense guidance.
Why it matters — A SGHT watcher would care because the company showed revenue growth across its key business lines while cutting costs and improving its full-year financial guidance.
Sight Sciences, Inc. reported a second-quarter loss of $0.08 per share, narrower than the Zacks Consensus Estimate of a $0.15 loss and improved from a $0.23 per share loss in the same period a year ago. The company also topped revenue estimates.
Why it matters — The quarterly loss came in better than analysts expected and improved year over year, giving SGHT watchers a more favorable read on recent performance.
The 7 Wall Street analysts covering Sight Sciences, Inc. have a median 12-month price target of $8, with estimates ranging from $8 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Sight Sciences, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sight Sciences, Inc. 90 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Sight Sciences, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (97 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies -1.7% from the last close, and Ticker Nerd's factor model ranks Sight Sciences, Inc. 90 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Sight Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SGHT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $12 over the next 12 months.
Sight Sciences, Inc. returned +124.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Sight Sciences, Inc. is an ophthalmic medical device company focused on developing and commercializing interventional technologies for glaucoma and dry eye disease.
The most recent item we track (GlobeNewsWire, 1 Sept 2026): "Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15". Sight Sciences, Inc. announced it will present at the upcoming Morgan Stanley Global Healthcare Conference in New York, NY. The presentation is scheduled for September 15.
Sight Sciences, Inc. is an ophthalmic medical device company focused on developing and commercializing interventional technologies for glaucoma and dry eye disease. Its current product portfolio includes the OMNI Surgical System family for minimally invasive glaucoma procedures, the SION Surgical Instrument for trabecular meshwork excision, and the TearCare System for treating evaporative dry eye associated with meibomian gland dysfunction. The company serves eyecare providers, including ophthalmologists and optometrists, by offering tools designed to address key causes of intraocular pressure buildup and tear-film dysfunction. Sight Sciences operates through its Surgical Glaucoma and Dry Eye segments, positioning its products across procedural eyecare settings where device-based treatment options are used to support patient care. Headquartered in Menlo Park, California, Sight Sciences plays a focused role in the medical technology market by supplying specialized devices for prevalent eye conditions.
CEO Mr. Paul Badawi · 186 employees · United States · https://www.sightsciences.com
